Selected research
Industry Research
Pancreatic Endocrine Tumor Drug Industry Research Report 2026
Market perspective
The global Pancreatic Endocrine Tumor Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pancreatic Endocrine Tumor Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pancreatic Endocrine Tumor Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pancreatic Endocrine Tumor Drug include Ipsen S.A., MediaPharma s.r.l., OXiGENE, Inc., Jiangsu Hengrui Medicine Co., Ltd. and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pancreatic Endocrine Tumor Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pancreatic Endocrine Tumor Drug Market by Company
Ipsen S.A.
MediaPharma s.r.l.
OXiGENE, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Pancreatic Endocrine Tumor Drug Segment by Type
Buparlisib Hydrochloride
Dovitinib Lactate
Fosbretabulin Tromethamine
Lanreotide Acetate
MPHE-001B
Others
Pancreatic Endocrine Tumor Drug Segment by Application
Clinic
Research Center
Hospital
Pancreatic Endocrine Tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pancreatic Endocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pancreatic Endocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pancreatic Endocrine Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pancreatic Endocrine Tumor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pancreatic Endocrine Tumor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pancreatic Endocrine Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Buparlisib Hydrochloride
- Dovitinib Lactate
- Fosbretabulin Tromethamine
- Lanreotide Acetate
- MPHE-001B
- Others
Applications
- Clinic
- Research Center
- Hospital
Companies covered
- Ipsen S.A.
- MediaPharma s.r.l.
- OXiGENE, Inc.
- Jiangsu Hengrui Medicine Co., Ltd.
- Novartis AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pancreatic Endocrine Tumor Drug Market Size (2021-2032)
- 2.2.2 Global Pancreatic Endocrine Tumor Drug Sales (2021-2032)
- 2.2.3 Global Pancreatic Endocrine Tumor Drug Market Average Price (2021-2032)
- 2.3 Pancreatic Endocrine Tumor Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Buparlisib Hydrochloride
- 2.3.3 Dovitinib Lactate
- 2.3.4 Fosbretabulin Tromethamine
- 2.3.5 Lanreotide Acetate
- 2.3.6 MPHE-001B
- 2.3.7 Others
- 2.4 Pancreatic Endocrine Tumor Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Research Center
- 2.4.4 Hospital
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pancreatic Endocrine Tumor Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pancreatic Endocrine Tumor Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Pancreatic Endocrine Tumor Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Pancreatic Endocrine Tumor Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Pancreatic Endocrine Tumor Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pancreatic Endocrine Tumor Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pancreatic Endocrine Tumor Drug, Product Type & Application
- 3.8 Global Manufacturers of Pancreatic Endocrine Tumor Drug, Established Date
- 3.9 Global Pancreatic Endocrine Tumor Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Ipsen S.A.
- 4.1.1 Ipsen S.A. Company Information
- 4.1.2 Ipsen S.A. Business Overview
- 4.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio
- 4.1.5 Ipsen S.A. Recent Developments
- 4.2 MediaPharma s.r.l.
- 4.2.1 MediaPharma s.r.l. Company Information
- 4.2.2 MediaPharma s.r.l. Business Overview
- 4.2.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio
- 4.2.5 MediaPharma s.r.l. Recent Developments
- 4.3 OXiGENE, Inc.
- 4.3.1 OXiGENE, Inc. Company Information
- 4.3.2 OXiGENE, Inc. Business Overview
- 4.3.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio
- 4.3.5 OXiGENE, Inc. Recent Developments
- 4.4 Jiangsu Hengrui Medicine Co., Ltd.
- 4.4.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
- 4.4.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
- 4.4.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio
- 4.4.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
- 4.5 Novartis AG
- 4.5.1 Novartis AG Company Information
- 4.5.2 Novartis AG Business Overview
- 4.5.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
- 4.5.5 Novartis AG Recent Developments
5 Global Pancreatic Endocrine Tumor Drug Market Scenario by Region
- 5.1 Global Pancreatic Endocrine Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021-2032
- 5.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021-2026
- 5.2.2 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2027-2032
- 5.3 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2021-2032
- 5.3.1 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2021-2026
- 5.3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2027-2032
- 5.4 North America Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
- 5.4.1 North America Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2032)
- 5.4.3 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
- 5.5.1 Europe Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pancreatic Endocrine Tumor Drug Sales by Country (2021-2032)
- 5.5.3 Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
- 5.7.1 South America Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2032)
- 5.7.3 South America Pancreatic Endocrine Tumor Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032)
- 6.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032)
- 6.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Pancreatic Endocrine Tumor Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032)
- 7.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032)
- 7.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Pancreatic Endocrine Tumor Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pancreatic Endocrine Tumor Drug Value Chain Analysis
- 8.1.1 Pancreatic Endocrine Tumor Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pancreatic Endocrine Tumor Drug Production Mode & Process
- 8.2 Pancreatic Endocrine Tumor Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pancreatic Endocrine Tumor Drug Distributors
- 8.2.3 Pancreatic Endocrine Tumor Drug Customers
9 Global Pancreatic Endocrine Tumor Drug Analyzing Market Dynamics
- 9.1 Pancreatic Endocrine Tumor Drug Industry Trends
- 9.2 Pancreatic Endocrine Tumor Drug Industry Drivers
- 9.3 Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges
- 9.4 Pancreatic Endocrine Tumor Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst